{"id":"W4404455235","doi":"10.25251/skin.8.supp.473","title":"Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Geotab (Canada)","funders":"LEO Pharma; InflaRx; Idorsia Pharmaceuticals; European Academy of Dermatology and Venereology; Eisai; Bundesministerium für Bildung und Forschung; Insmed; Incyte; Celgene; Biogen; L'Oreal USA; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Open label; Extension (predicate logic); Phase (matter); Medicine; Dermatology; Internal medicine; Clinical trial; Computer science; Chemistry; Programming language","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003631529,0.0003776321,0.001360681,0.0001535204,0.0002886136,0.00009120027,0.0002719563,0.0001317682,0.0001935136],"category_scores_gemma":[0.00183179,0.0001658217,0.00006289746,0.0004130361,0.0005439027,0.0003248505,0.0001553332,0.0007828069,0.000005772798],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001404267,"about_ca_system_score_gemma":0.000234261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005836948,"about_ca_topic_score_gemma":0.0001427693,"domain_scores_codex":[0.9960874,0.0008382938,0.001376248,0.000381751,0.0009684598,0.0003478145],"domain_scores_gemma":[0.9946439,0.003978253,0.0004696708,0.000470455,0.0001951941,0.0002424883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"case_report","study_design_scores_codex":[0.255284,0.006577853,0.002525723,0.0002168841,0.005028888,0.1963061,0.1540296,0.000008261968,0.006868894,0.0002041504,0.124792,0.2481577],"study_design_scores_gemma":[0.3179425,0.05008887,0.02088242,0.0166504,0.006452021,0.4376811,0.006598102,0.0001398757,0.0006670238,0.001688484,0.1402499,0.0009593783],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.849655,0.006902101,0.00003546671,0.1409672,0.0004156545,0.001448925,0.0002816867,0.00001902905,0.0002749367],"genre_scores_gemma":[0.9943468,0.003352648,0.0005848855,0.0003419117,0.0005143434,0.000005061554,0.0001469528,0.00005443468,0.0006529384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2471983,"threshold_uncertainty_score":0.6762012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07663420508063443,"score_gpt":0.3691144696220155,"score_spread":0.2924802645413811,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}